Vulvar squamous cell hyperplasia Trials in Disease

Study on HPV Vaccine for Women with Vulvar HSIL: Evaluating the Effectiveness of Nonavalent HPV Vaccine in Preventing Recurrence of Vulvar High-Grade Lesions

This trial is investigating whether the Gardasil 9 vaccine, also known as the nonavalent HPV vaccine, can help prevent the recurrence of vulvar high-grade squamous intraepithelial lesions (vHSIL) in women who have already been treated for this condition. The condition involves abnormal changes in the skin cells of the vulva that are considered precancerous and are often linked to certain types of human papillomavirus (HPV).

Who can participate:

• Women who are 18 years or older
• Those who have a confirmed diagnosis of vulvar high-grade squamous intraepithelial lesion through medical testing
• Women who are scheduled for treatment, which may include surgery, laser therapy, or a topical cream called imiquimod

Who cannot participate:

• Men or individuals who are not women
• Those without a confirmed diagnosis of vHSIL
• Individuals who fall outside the specified age range for the study
• People belonging to vulnerable populations that may require special protection

What the trial involves:

The main goal of this study is to determine whether the HPV vaccine can effectively prevent the return of high-grade lesions after women have received their initial treatment. Participants will be randomly assigned to receive either the Gardasil 9 vaccine or a placebo (an inactive substance). The vaccine protects against nine different types of HPV that are known to cause various cancers and genital warts.

After receiving their initial treatment for vHSIL, participants will get an injection of either the vaccine or placebo directly into a muscle. They will then be monitored through regular follow-up visits at 6, 12, and 24 months to check for any recurrence of the condition. During these visits, researchers will also assess the presence of different HPV types, evaluate quality of life, and monitor any need for additional treatment.

The study will compare how many women experience a return of vHSIL in the vaccine group versus the placebo group. Researchers will also examine how the vaccine affects HPV antibody levels and whether it has any impact on participants' sexual health and overall well-being. The trial is expected to conclude by January 2029.

Investigational treatment: The nonavalent HPV vaccine (Gardasil 9) is administered through a muscle injection and is designed to stimulate the immune system to recognize and fight nine types of human papillomavirus. This prophylactic vaccine aims to prevent disease by reducing the risk of developing HPV-related lesions.

Summary

Currently, there is one active clinical trial for vulvar squamous cell hyperplasia, taking place in the Netherlands. This trial represents an important area of research focusing on prevention of recurrence rather than initial treatment. The study specifically targets women who have already undergone treatment for high-grade lesions and investigates whether the nonavalent HPV vaccine can provide protection against the condition returning.

The focus on HPV vaccination reflects growing understanding of the role that human papillomavirus plays in developing abnormal vulvar cell changes. By following participants for up to 24 months, researchers hope to gather valuable evidence about whether vaccination can be an effective preventive strategy for women who have been treated for this precancerous condition.